If eligibility for germline testing is instead based upon the NHS National Genomic Test Directory (indication R210) [16], this includes all patients whose MLH1-deficient/MSI-High tumours are BRAF wild-type (i.e. skipping MLH1 promoter methylation testing). This evidence concerns the gene MLH1 and neoplasm.